All In Biotech

Drug Trial Radar · NCT04736758

A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza

Last checked: Nov 19, 2026Latest source record: Jul 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 216 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

216

Actual

Start

Jan 8, 2021

Primary completion

Dec 18, 2021

Study completion Dec 18, 2021

Sponsor

Sponsor type
Industry
First posted
Feb 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Analyse the time of flu symptom relief in adults with uncomplicated acute influenza,to evaluate the antiviral effects of high and low doses of GP681 tablets, and explore the optimal dose for phase III clinical trials.

Conditions

  • Influenza

Interventions

  • GP681 tabletDrug

    influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.

  • GP681 SimulantDrug

    influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. time to alleviation of influenza symptomsTime frame: Day 15

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.